Table 2.
Parameters | Time | Group | P value | Mean difference* (95% CI) |
|
---|---|---|---|---|---|
Drug | Placebo | ||||
Pain severity |
Baseline (week 0) End (week 4) P-value |
16 [13–18] 4 [2–7.5] < 0.001c |
15 [10–19] 8 [4–17.5] < 0.001c |
0.958a 0.001b |
3.91 ± 1.44 (1.02–6.80) |
Flexibility |
Baseline (week 0) End (week 4) P-value |
6 [4–7] 2 [0–2] < 0.001c |
6 [4–8] 4 [1.5–6] < 0.001c |
0.356a 0.001b |
1.84 ± 0.50 (0.83–2.85) |
Function |
Baseline (week 0) End (week 4) P-value |
46.54 ± 11.24 22.30 ± 15.48 < 0.001d |
47.68 ± 11.55 36.00 ± 18.40 < 0.001d |
0.68b < 0.001b |
13.70 ± 4.09 (5.53–21.86) |
Total score of WOMAC |
Baseline (week 0) End (week 4) P-value |
67 [58–79] 24 [15–36.5] < 0.001c |
70 [54–83.5] 52 [25–74] < 0.001c |
0.646a 0.001b |
19.08 ± 5.71 (7.67–30.48) |
VAS score |
Baseline (week 0) End (week 4) P-value |
9 [7–10] 4 [2.5–5] < 0.001c |
9 [8–9.5] 6 [3.5–9] < 0.001c |
0.804a 0.001b |
1.92 ± 0.62 (0.67–3.16) |
PGA score |
Baseline (week 0) End (week 4) P-value |
3 [2.5–4] 1.8 [1–2.5] < 0.001c |
3.5 [3, 4] 3 [1.9–3.5] < 0.001c |
0.918a 0.001b |
0.78 ± 0.26 (0.26–1.30) |
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, VAS visual analogue scale, PGA patient global assessment
aMann-Whithney U test
bANCOVA test
cWilcoxon Signed Rank test
dPaired Sample T-test
*Mean ± SE of difference for end values according to ANCOVA test